PHIO PHARMACEUTICALS CORP (PHIO) Stock Fundamental Analysis

NASDAQ:PHIO • US71880W5013

1.08 USD
+0.06 (+5.88%)
At close: Feb 24, 2026
1.09 USD
+0.01 (+0.93%)
After Hours: 2/24/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PHIO. PHIO was compared to 521 industry peers in the Biotechnology industry. PHIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • PHIO had negative earnings in the past year.
  • In the past year PHIO has reported a negative cash flow from operations.
  • In the past 5 years PHIO always reported negative net income.
  • PHIO had a negative operating cash flow in each of the past 5 years.
PHIO Yearly Net Income VS EBIT VS OCF VS FCFPHIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • PHIO's Return On Assets of -69.13% is on the low side compared to the rest of the industry. PHIO is outperformed by 62.38% of its industry peers.
  • PHIO has a Return On Equity (-80.83%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -69.13%
ROE -80.83%
ROIC N/A
ROA(3y)-110.57%
ROA(5y)-88.07%
ROE(3y)-133.2%
ROE(5y)-105.54%
ROIC(3y)N/A
ROIC(5y)N/A
PHIO Yearly ROA, ROE, ROICPHIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PHIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHIO Yearly Profit, Operating, Gross MarginsPHIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for PHIO has been increased compared to 1 year ago.
  • Compared to 5 years ago, PHIO has more shares outstanding
  • There is no outstanding debt for PHIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PHIO Yearly Shares OutstandingPHIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
PHIO Yearly Total Debt VS Total AssetsPHIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • Based on the Altman-Z score of -16.00, we must say that PHIO is in the distress zone and has some risk of bankruptcy.
  • PHIO has a worse Altman-Z score (-16.00) than 80.04% of its industry peers.
  • There is no outstanding debt for PHIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16
ROIC/WACCN/A
WACCN/A
PHIO Yearly LT Debt VS Equity VS FCFPHIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • PHIO has a Current Ratio of 6.90. This indicates that PHIO is financially healthy and has no problem in meeting its short term obligations.
  • PHIO has a better Current ratio (6.90) than 69.10% of its industry peers.
  • A Quick Ratio of 6.90 indicates that PHIO has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 6.90, PHIO is doing good in the industry, outperforming 69.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.9
Quick Ratio 6.9
PHIO Yearly Current Assets VS Current LiabilitesPHIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • PHIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.87%, which is quite impressive.
EPS 1Y (TTM)81.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, PHIO will show a very strong growth in Earnings Per Share. The EPS will grow by 23.91% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y75.37%
EPS Next 2Y35.74%
EPS Next 3Y23.91%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHIO Yearly Revenue VS EstimatesPHIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2023 20M 40M 60M
PHIO Yearly EPS VS EstimatesPHIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50K -100K -150K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PHIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHIO Price Earnings VS Forward Price EarningsPHIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHIO Per share dataPHIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • PHIO's earnings are expected to grow with 23.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.74%
EPS Next 3Y23.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHIO PHARMACEUTICALS CORP

NASDAQ:PHIO (2/24/2026, 8:00:00 PM)

After market: 1.09 +0.01 (+0.93%)

1.08

+0.06 (+5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners7.24%
Inst Owner Change87.61%
Ins Owners3.73%
Ins Owner Change55.58%
Market Cap11.62M
Revenue(TTM)N/A
Net Income(TTM)-7.95M
Analysts82.86
Price Target14.28 (1222.22%)
Short Float %6.3%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.2%
Min EPS beat(2)-22.55%
Max EPS beat(2)4.14%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.66%
EPS NY rev (1m)0%
EPS NY rev (3m)13.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)-6.48
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.13%
ROE -80.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-110.57%
ROA(5y)-88.07%
ROE(3y)-133.2%
ROE(5y)-105.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -41.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.9
Quick Ratio 6.9
Altman-Z -16
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)76.79%
Cap/Depr(5y)64.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.43%
EPS Next Y75.37%
EPS Next 2Y35.74%
EPS Next 3Y23.91%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.68%
EBIT Next 3Y-17.49%
EBIT Next 5YN/A
FCF growth 1Y34.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.43%
OCF growth 3YN/A
OCF growth 5YN/A

PHIO PHARMACEUTICALS CORP / PHIO FAQ

Can you provide the ChartMill fundamental rating for PHIO PHARMACEUTICALS CORP?

ChartMill assigns a fundamental rating of 2 / 10 to PHIO.


What is the valuation status for PHIO stock?

ChartMill assigns a valuation rating of 1 / 10 to PHIO PHARMACEUTICALS CORP (PHIO). This can be considered as Overvalued.


What is the profitability of PHIO stock?

PHIO PHARMACEUTICALS CORP (PHIO) has a profitability rating of 0 / 10.


How financially healthy is PHIO PHARMACEUTICALS CORP?

The financial health rating of PHIO PHARMACEUTICALS CORP (PHIO) is 6 / 10.